Faron appoints Marie-Louise Fjällskog as Chief Marketing Officer – QNT Press Release

Turku, Finland and Boston, January 3, 2022 /PRNewswire/ – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) is a clinical-stage biopharmaceutical company focused on building the future of immunotherapy by using the power of the immune system to deal with cancer and inflammation. I am pleased to announce the appointment of Marie-Louise Fjällskog, MD, Ph.D. as the company’s chief medical officer. Dr. Fjällskog will be at Boston, Massachusetts Her appointment is effective immediately.

Dr. Fjällskog has more than 30 years of experience in clinical oncology, translational research, and drug development. She joined Faron from Sensei Biotherapeutics (SNSE), a major immuno-oncology biopharmaceutical company listed on NASDAQ. As the chief medical officer of Sensei, she is responsible for leading clinical and development strategy and operations.She also played a key role in the success of Sensei US$152 million IPO, which closed February 2021. Dr. Fjällskog has a doctorate and a doctorate in medicine Uppsala University, Sweden She is currently an associate professor of oncology.

In her new role, Dr. Fjällskog will join Faron’s management team and provide leadership and guidance to accelerate the company’s clinical development plans.Her main focus will be BemalimumabA new precision cancer immunotherapy candidate drug wholly-owned by Faron is currently under development as a potential monotherapy for patients with solid tumors. Faron is also advancing the learning plan Bemalimumab In neoadjuvant therapy, it is used in combination with checkpoint inhibitors to treat hematological malignancies.

“I am very happy to welcome Marie-Louise to Faron as our chief medical officer, because we are accelerating the execution of our ambitious clinical development plan, including our major oncology assets, which is a critical period for the company Bemalimumab,” said the doctor. Marku Jalkanin, CEO of Faron. “With her extensive experience in oncology clinical development, she can professionally help advance our plans and progress. We hope this will become the first macrophage-targeted immunotherapy for patients with difficult-to-treat cancer.”

“Faron’s new immunotherapy plan may open up a new era of cancer treatment by unlocking the “hidden me” signal produced by bone marrow cells and initiating an immune response in indications that have proven resistance to current checkpoint inhibitor therapies. “Mary said. Louise Fjällskog, MD, PhD “I am very happy to join the company at such an exciting time and look forward to helping accelerate development Bemalimumab As monotherapy and in combination with other checkpoint inhibitors, this may further expand and Bemalimumab Alone. ”

Prior to joining Sensei Biotherapeutics, Dr. Fjällskog served as Vice President of Clinical Development for Merus (MRUS) and Infinity Pharmaceuticals (INFI), leading the development of multiple small molecule and immunotherapy clinical projects, and was responsible for the prioritization of preclinical research. She It used to be a global clinical…

The full story can be found on Benzinga.com

Source link

Recommended For You

About the Author: News Center